Real-life experience of ledipasvir and sofosbuvir single-tablet regimen among chronic hepatitis C patients in Turkey


Yamazhan T., TURAN İ., Ersoz G., Gunsar F., Pullukcu H., Danis N., ...More

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.31, no.3, pp.239-246, 2020 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 31 Issue: 3
  • Publication Date: 2020
  • Doi Number: 10.5152/tjg.2020.19076
  • Journal Name: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.239-246
  • Keywords: Ledipasvir, Turkey, sofosbuvir, chronic hepatitis C, effectiveness, safety, ADVANCED LIVER-DISEASE, GENOTYPE 1, WORLD EFFECTIVENESS, PLUS RIBAVIRIN, RISK-FACTORS, HCV, LEDIPASVIR/SOFOSBUVIR, MULTICENTER, INFECTIONS
  • Dokuz Eylül University Affiliated: No

Abstract

Background/Aims: Ledipasvir (LDV) and sofosbuvir (SOF) as single-tablet regimen (STR) has been approved for treatment of chronic HCV infection (CHC) for treatment-naive or experienced cirrhotic or non-cirrhotic patients. Our aim was to analyse the effectiveness and safety of 12-24 weeks treatment of LDV/SOF (90mg/400 mg)+/- ribavirin in a real-life setting in Turkey.